Treatment of essential hypertension.
AMOTAN-H FC TABLET
Add-on therapy
OLMEXA PLUS is indicated in adult patients whose blood pressure is not adequately controlled on the combination of
olmesartan medoxomil and amlodipine taken as dual-component formulation.
Substitution therapy
OLMEXA PLUS is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the
combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (Olmesartan medoxomil and amlodipine or olmesart
Treatment of essential hypertension.
AMOTAN-H FC TABLET
Add-on therapy
OLMEXA PLUS is indicated in adult patients whose blood pressure is not adequately controlled on the combination of
olmesartan medoxomil and amlodipine taken as dual-component formulation.
Substitution therapy
OLMEXA PLUS is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the
combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (Olmesartan medoxomil and amlodipine or olmesart
Treatment of essential hypertension.
AMOTAN-H FC TABLET
Add-on therapy
OLMEXA PLUS is indicated in adult patients whose blood pressure is not adequately controlled on the combination of
olmesartan medoxomil and amlodipine taken as dual-component formulation.
Substitution therapy
OLMEXA PLUS is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the
combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (Olmesartan medoxomil and amlodipine or olmesart
Treatment of essential hypertension.
AMOTAN-H FC TABLET
Add-on therapy
OLMEXA PLUS is indicated in adult patients whose blood pressure is not adequately controlled on the combination of
olmesartan medoxomil and amlodipine taken as dual-component formulation.
Substitution therapy
OLMEXA PLUS is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the
combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (Olmesartan medoxomil and amlodipine or olmesart
Treatment of essential hypertension.
AMOTAN-H FC TABLET
Add-on therapy
OLMEXA PLUS is indicated in adult patients whose blood pressure is not adequately controlled on the combination of
olmesartan medoxomil and amlodipine taken as dual-component formulation.
Substitution therapy
OLMEXA PLUS is indicated as substitution therapy in adult patients whose blood pressure is adequately controlled on the
combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide, taken as a dual-component (Olmesartan medoxomil and amlodipine or olmesart
Efavirenz is indicated in antiviral combination treatment of human immunodeficiency virus 1
(HIV 1) infected adults, adolescents and children 3 months of age and older and weighing at least 3.5 kg.
Efavirenz has not been adequately studied in patients with advanced HIV disease, namely in patients with CD4 counts < 50 cells/mm 3, or after failure of protease inhibitor (PI) containing
regimens. Although cross resistance of Efavirenz with PIs has not been documented, there are at present insufficient data on the efficacy of subsequent use of PI based combination therapy after
failure of regimens containing Efavirenz.
For a summary of clinical and pharmacodynamic information.
Treatment of essential hypertension.
is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.
Treatment of essential hypertension.
is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.
Treatment of essential hypertension.
is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil or amlodipine monotherapy.
Adults Treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. Paediatric population Treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary
haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease